Project Grant R01CA303720
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $704K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $370,173 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 9, 2025, with a completion date of August 31, 2030. This project delivers research and development of advanced genetic interaction measurement and characterization methodologies for cancer cells, with a primary focus on synthetic lethality as a...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 1, 2026, with completion targeted for May 31, 2028. This award supports the development of novel statistical methodologies and software tools to enhance risk assessment for rare cancer patients at individual medical institutions by adaptively leveraging data...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $498,565 Project Grant to The University of Texas MD Anderson Cancer Center on September 8, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a Globally Accessible and Pragmatic Predictive Signature (GAPPS) for locally advanced cervical cancer. The project, which extends through July 31, 2029, addresses a critical clinical need to risk-stratify cervical cancer patients undergoing...
- Federal Project Grant Award Summary The National Cancer Institute awarded Am Operating LLC a Project Grant of $1.116M (awarded August 1, 2025; completion July 31, 2027) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop a standardized visualization, labeling, and tracking system for documenting skin cancer anatomic locations. The project delivers a technological platform that creates reproducible, standardized descriptions of skin cancer biopsy sites using...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $616,715 to The University of Texas MD Anderson Cancer Center, with an award date of August 11, 2025 and completion date of July 31, 2030. This award supports research under the Cancer Treatment Research program (CFDA 93.395), which develops and evaluates improved methods of cancer treatment through fundamental and applied laboratory and clinical research. The funded research centers on the...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $680,129 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026 through March 31, 2031. This award supports the development of drug-loaded degradable biopolymeric scaffolds designed to augment preoperative liver growth in cancer patients undergoing hepatic resection. The research addresses critical challenges in liver tumor...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $2.46 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) on August 18, 2025, for the INHANCE (Imaging Innovation for Head and Neck Cancer Evaluation & Treatment Delivery) initiative, with a completion date of July 31, 2030. This award supports the development and implementation of advanced imaging technologies and computational image analysis methods to...
- Summary of Federal Project Grant Award The University of Texas MD Anderson Cancer Center received a $510,671 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective May 1, 2026 through April 30, 2031. This award supports research on the functional characterization of lineage plasticity in cholangiocarcinoma (CCA), a highly lethal bile duct cancer. The project will generate a comprehensive functional landscape of CCA...